YOU WONT BELIEVE: 2 | Mind Blowing Facts

Dr. Reddy's Generic HIV Prevention Shot Wins Tentative FDA Approval at $40 a Year in 120 Countries

The FDA has tentatively approved Dr. Reddy's generic injectable lenacapavir for HIV prevention, potentially bringing a twice-yearly shot costing about $40 annually to 120 countries.

Medical Daily · Nov 4

Emcure Pharma shares jump 7% after Q2 profit rises 29% YoY to Rs 325 crore

Emcure Pharmaceuticals shares rose up to 7.3% after the company reported a 29.3% year-on-year increase in Q2 FY27 profit to Rs 325.1 crore. Revenue grew 24.3%, while EBITDA rose 30.9%, supported by strong international business growth.

The Economic Times · Nov 3

Bonus issue alert! Choice International to reward shareholders with 1:1 bonus shares. Check details

Choice International has approved a 1:1 bonus issue, its first such corporate action in two years. Under the proposal, shareholders will receive one bonus share for every share held on the record date, which will be announced later. The move will double the number of outstanding shares without changing the…

The Economic Times · Nov 3

GLP-1 Focus or Broader Peptide Exposure: Which ETF Has the Edge?

Compares the Roundhill GLP-1 & Weight Loss ETF (OZEM) and the newer REX Peptide ETF (PEPT), examining holdings, fees, and overlap as GLP-1 drug demand from Eli Lilly and Novo Nordisk continues to grow.

MarketBeat · Nov 2

Generic HIV prevention shot approved in major step to end global epidemic

The drug is expected to cost $40 a year per person in the countries where it will be available

The Independent UK · Nov 2

US approves cheap generic version of breakthrough HIV prevention jab – in major step towards ending Aids

The Lenacapavir injection will cost just $40 a year in 120 countries, in what is seen as a major step towards ending Aids

The Independent UK · Nov 2

HHS Just Opened Temporary Peptide Compounding. Pharmacist and CEO of Precision Medicine Explains What Patients Need to Know

Peptide rules have shifted again and again, from advisory committee votes to a temporary policy HHS released on October 28. Christian Stella, PharmD, CEO and co-founder of Precision Medicine, works with both the medication and the policy, and explains what the change means for patients and providers.

Medical Daily · Nov 2

Wockhardt expands novel antibiotic Miqnaf's access; Q2 revenue rises 24%

Wockhardt has expanded its marketing access for Miqnaf in India following the removal of a supply condition. The company's biotechnology sector recorded significant revenue growth, indicating strong demand for its products. Zaynich received US FDA approval for complicated urinary tract infections, serving as a milestone for Indian pharmaceuticals.

The Economic Times · Nov 2

FDA Approves Preservative-Free Generic Ketamine as Hospital Shortage Continues

The FDA approved a preservative-free generic ketamine injection from NRx Pharmaceuticals as hospitals continue managing a shortage that has persisted since 2018.

Medical Daily · Nov 1

Eli Lilly’s First Full Medicare Quarter: Is Volume Still Outrunning Price Cuts?

Eli Lilly posted 39% YOY revenue growth in Q3 2026 on strong Mounjaro and Zepbound sales, raising full-year guidance even as Medicare's GLP-1 Bridge program pressures drug pricing.

MarketBeat · Nov 1